CL2014002668A1 - Método de tratamiento del cáncer que comprende administrar 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7(8h)-ona y n-((s)-2,3-dihidroxipropil)-3-(2-fluoro-4-yodo-fenilamino)isonicotinamida; composicion farmaceutica; uso de una combinacion para tratar cancer tal como cancer de pulmon, cancer de mama triple negativo, entre otros. - Google Patents

Método de tratamiento del cáncer que comprende administrar 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7(8h)-ona y n-((s)-2,3-dihidroxipropil)-3-(2-fluoro-4-yodo-fenilamino)isonicotinamida; composicion farmaceutica; uso de una combinacion para tratar cancer tal como cancer de pulmon, cancer de mama triple negativo, entre otros.

Info

Publication number: CL2014002668A1
Authority: CL; Chile
Prior art keywords: cancer; isonicotinamide; dihydroxypropyl; pyrido; phenylamino
Prior art date: 2012-04-06

Application number

CL2014002668A

Other languages

English (en)

Inventor

Janet Anne Meurer Ogden

Joanne Lager

Karl Hsu

Original Assignee

Merck Patent Gmbh

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-06

Filing date

2014-10-03

Publication date

2015-01-16

2014-10-03 Application filed by Merck Patent Gmbh, Sanofi Sa filed Critical Merck Patent Gmbh

2015-01-16 Publication of CL2014002668A1 publication Critical patent/CL2014002668A1/es

Links

206010028980 Neoplasm Diseases 0.000 title 2
201000011510 cancer Diseases 0.000 title 2
-1 (s) -2,3-dihydroxypropyl Chemical group 0.000 title 1
RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 title 1
206010058467 Lung neoplasm malignant Diseases 0.000 title 1
208000003721 Triple Negative Breast Neoplasms Diseases 0.000 title 1
201000005202 lung cancer Diseases 0.000 title 1
208000020816 lung neoplasm Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
208000022679 triple-negative breast carcinoma Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2014002668A 2012-04-06 2014-10-03 Método de tratamiento del cáncer que comprende administrar 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7(8h)-ona y n-((s)-2,3-dihidroxipropil)-3-(2-fluoro-4-yodo-fenilamino)isonicotinamida; composicion farmaceutica; uso de una combinacion para tratar cancer tal como cancer de pulmon, cancer de mama triple negativo, entre otros. CL2014002668A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201261621252P	2012-04-06	2012-04-06
FR1351158		2013-02-12
US201361771457P	2013-03-01	2013-03-01

Publications (1)

Publication Number	Publication Date
CL2014002668A1 true CL2014002668A1 (es)	2015-01-16

Family

ID=49301040

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002668A CL2014002668A1 (es)	2012-04-06	2014-10-03	Método de tratamiento del cáncer que comprende administrar 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7(8h)-ona y n-((s)-2,3-dihidroxipropil)-3-(2-fluoro-4-yodo-fenilamino)isonicotinamida; composicion farmaceutica; uso de una combinacion para tratar cancer tal como cancer de pulmon, cancer de mama triple negativo, entre otros.

Country Status (18)

Country	Link
US (1)	US20150031882A1 (es)
EP (1)	EP2854854A1 (es)
JP (1)	JP2015515476A (es)
KR (1)	KR20150003786A (es)
CN (1)	CN104334192A (es)
AU (1)	AU2013243429A1 (es)
CA (1)	CA2869152A1 (es)
CL (1)	CL2014002668A1 (es)
CO (1)	CO7121349A2 (es)
CR (1)	CR20140480A (es)
DO (1)	DOP2014000221A (es)
EA (1)	EA201491836A1 (es)
MX (1)	MX2014012001A (es)
PE (1)	PE20142020A1 (es)
PH (1)	PH12014502219A1 (es)
SG (1)	SG11201406199TA (es)
TN (1)	TN2014000418A1 (es)
WO (1)	WO2013152165A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11007183B2 (en)	2013-12-20	2021-05-18	Biomed Valley Discoveries, Inc.	Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors
EP3363911B1 (en) *	2015-10-14	2024-09-25	Nitto Boseki Co., Ltd.	Method for determining drug-sensitive human breast cancer cells by analysis method in which measurement of activity of two types of protein kinase is used

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA200703912B (en)	2004-10-20	2008-09-25	Serono Lab	3-arylamino pyridine derivatives
US7989622B2 (en)	2005-10-07	2011-08-02	Exelixis, Inc.	Phosphatidylinositol 3-kinase inhibitors and methods of their use
EA016945B1 (ru) *	2005-10-07	2012-08-30	Экселиксис, Инк.	ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
CA2776944A1 (en) *	2009-10-12	2011-05-12	F. Hoffmann-La Roche Ag	Combinations of a pi3k inhibitor and a mek inhibitor
AR084216A1 (es) *	2010-12-09	2013-05-02	Sanofi Sa	Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit

2013
- 2013-04-04 AU AU2013243429A patent/AU2013243429A1/en not_active Abandoned
- 2013-04-04 EP EP13717123.7A patent/EP2854854A1/en not_active Withdrawn
- 2013-04-04 SG SG11201406199TA patent/SG11201406199TA/en unknown
- 2013-04-04 EA EA201491836A patent/EA201491836A1/ru unknown
- 2013-04-04 PE PE2014001533A patent/PE20142020A1/es not_active Application Discontinuation
- 2013-04-04 WO PCT/US2013/035231 patent/WO2013152165A1/en not_active Ceased
- 2013-04-04 KR KR20147030877A patent/KR20150003786A/ko not_active Withdrawn
- 2013-04-04 JP JP2015504716A patent/JP2015515476A/ja active Pending
- 2013-04-04 CN CN201380029317.1A patent/CN104334192A/zh active Pending
- 2013-04-04 MX MX2014012001A patent/MX2014012001A/es unknown
- 2013-04-04 CA CA2869152A patent/CA2869152A1/en not_active Abandoned
2014
- 2014-10-01 DO DO2014000221A patent/DOP2014000221A/es unknown
- 2014-10-01 PH PH12014502219A patent/PH12014502219A1/en unknown
- 2014-10-02 US US14/504,970 patent/US20150031882A1/en not_active Abandoned
- 2014-10-02 TN TN2014000418A patent/TN2014000418A1/fr unknown
- 2014-10-03 CL CL2014002668A patent/CL2014002668A1/es unknown
- 2014-10-16 CR CR20140480A patent/CR20140480A/es unknown
- 2014-10-29 CO CO14239743A patent/CO7121349A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
MX2014012001A (es)	2015-05-11
CR20140480A (es)	2014-11-17
CO7121349A2 (es)	2014-11-20
EA201491836A1 (ru)	2015-02-27
SG11201406199TA (en)	2014-10-30
PH12014502219A1 (en)	2015-01-12
DOP2014000221A (es)	2014-12-15
AU2013243429A1 (en)	2014-10-23
TN2014000418A1 (en)	2016-03-30
US20150031882A1 (en)	2015-01-29
CN104334192A (zh)	2015-02-04
KR20150003786A (ko)	2015-01-09
CA2869152A1 (en)	2013-10-10
PE20142020A1 (es)	2014-12-24
JP2015515476A (ja)	2015-05-28
WO2013152165A1 (en)	2013-10-10
EP2854854A1 (en)	2015-04-08

Similar Documents

Publication	Publication Date	Title
UY35115A (es)	2014-05-30	Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
CL2014001752A1 (es)	2014-10-10	Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
IL239488A0 (en)	2015-08-31	A gpc3-targeted medicinal agent for the treatment of patients for whom treatment with a gpc3-targeted medicinal agent is beneficial
CL2015001731A1 (es)	2015-08-28	Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
MX2015017201A (es)	2016-04-06	Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
CL2014001829A1 (es)	2015-01-02	Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
MX366899B (es)	2019-07-30	Nuevos compuestos.
WO2013170068A3 (en)	2014-02-20	Nuclear transport modulators and uses thereof
EA033374B1 (ru)	2019-10-31	Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
IL235593B (en)	2019-06-30	Factor 4 of a blood platelet that interacts with the parenoid for the treatment of side effects as a result of inhibiting the formation of blood cells due to an antineoplastic treatment regimen in cancer patients
NZ631144A (en)	2016-12-23	Compositions and methods for transmucosal absorption
GB2515439B (en)	2017-08-23	Vesicular formulations for use in the treatment of reduced mobility
AR085616A1 (es)	2013-10-16	Composicion farmaceutica inhalable que comprende glicopirrolato, uso
PH12015501341A1 (en)	2015-09-07	Chlorin derivative useful in photodynamic therapy and diagnosis
EP3318879A4 (en)	2018-11-21	Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag
GB201511770D0 (en)	2015-08-19	Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
EA201600318A1 (ru)	2016-09-30	Циклические тиеноурацилкарбоксамиды и их применение
MX2015013155A (es)	2016-04-04	Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
IN2014MN01568A (es)	2015-05-08
GB2515440B (en)	2017-02-08	Vesicular Formulations for use in the treatment of Rosacea
CL2014002668A1 (es)	2015-01-16	Método de tratamiento del cáncer que comprende administrar 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7(8h)-ona y n-((s)-2,3-dihidroxipropil)-3-(2-fluoro-4-yodo-fenilamino)isonicotinamida; composicion farmaceutica; uso de una combinacion para tratar cancer tal como cancer de pulmon, cancer de mama triple negativo, entre otros.
CO6731081A2 (es)	2013-08-15	Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
BR112014029838A2 (pt)	2017-06-27	formas no estado sólido de n-((s)-2,3-di-hidróxi-propil)-3-(2-flúor-4-iodo-fenilamino)- isonicotinamida
MX355719B (es)	2018-04-27	Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.
PT2870164T (pt)	2016-12-21	Derivados de imidazo[2,1-b]tiazol, as suas preparações e utilização como medicamentos